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187 Ochrobactrum and Agrobacterium spp.: emerging opportunistic
pathogens in cystic ﬁbrosis patients?
C. Teyssier1, E. Jumas-Bilak1, F. Counil2, A. Masnou1, L. Aleyrangues3,
R. Chiron2, H. Marchandin1,3. 1Laboratoire de Bacte´riologie, EA 3755, Faculte´
de Pharmacie, Montpellier, France; 2CRCM, CHU, Montpellier, France;
3Laboratoire de Bacte´riologie, CHU, Montpellier, France
The genus Ochrobactrum and Agrobacterium radiobacter consist in Gram-negative
rods. Ochrobactrum spp. are described as one of the most resistant Gram-negative
rods. Although recognized as opportunistic pathogens, Ochrobactrum and A. radio-
bacter have received little attention during cystic ﬁbrosis (CF) since one and four
isolates are reported, respectively.
The aim of this study was to describe clinical and microbiological features of these
bacteria in order to precise their clinical impact and their epidemiology in CF.
The strains were isolated during standard sputum analysis in CF patients; they were
identiﬁed by both phenotypic and molecular methods and compared by pulsed-ﬁeld
gel electrophoresis (PFGE).
During a 4-year period, 16 Ochrobactrum and 10 A. radiobacter strains were isolated
from 7 and 9 patients, respectively among the 200 patients analyzed. Ochrobactrum
anthropi was cultured from samples of all the 7 patients together with Ochrobactrum
intermedium (1 patient) or Ochrobactrum pseudogrignonense (1 patient). They were
associated to other opportunistic pathogens or not. Two cases of chronic colonization
by O. anthropi were proved by PFGE. Cross-contamination did not occur between
patients. Clinical data were also reviewed.
Ochrobactrum spp. and A. radiobacter were more frequently isolated from res-
piratory tract during CF than in other patients. O. intermedium and O. pseudo-
grignonense were reported here for the ﬁrst time in CF.
188 Large antibacterial spectrum of aminosterols derivatives towards
multidrug resistant Gram-negative and Gram-positive bacteria
from patients with cystic ﬁbrosis
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Resistance to antibiotics is a life-threatening danger with more severe impacts on
fragilized populations like cystic ﬁbrosis (CF) patients. Squalamine and AminoS-
terol Derivatives (ASDs) have demonstrated interesting antibacterial activity against
bacterial reference strains. We provide herein the ﬁrst report about the activity
of squalamine 1 and two synthesized ASDs 2, 3 against 135 clinical strains of
multidrug resistant Gram-negative and -positive bacteria. Further, we gained insight
into their mechanism of action using Transmision Electron Microscopy (TEM). In
the case of Gram-negative bacteria, MICs ranged from 2 to 128mg/L. Mucoidity of
P. aeruginosa strains and resistance to colistin signiﬁcantly correlated with elevated
MICs for tested compounds. In contrast, compounds 1−3 appeared very active
against various Gram-positive bacteria with highest MIC value of 8mg/L. TEM
images revealed a membrane-disruptor effect of ASDs on S. aureus and altered
membrane shape in treated P. aeruginosa. In spite of correlating with colistin in
activity against Gram-negative bacteria, compounds 1−3 demonstrated surprising
higher effect against Gram-positive isolates naturally resistant to colistin. Moreover,
TEM images showed that ASDs affect differently the membrane of tested S. aureus
and P. aeruginosa isolates. Taken together, our results indicate that ASDs possess
a broad antibacterial spectrum with probably different mechanism of action against
both Gram-negative and -positive bacteria. Further work is warranted to fully
elucidate their mechanism of action and optimize their structure.
189 Human Neutrophil Peptide-1 (HNP-1) and a truncated analogue
display antimicrobial activity against respiratory pathogens
F.T. Lundy1, M.M. Tunney2, C.C. Taggart1, J.S. Elborn1. 1Centre for Infection
and Immunity, Queen’s University, Belfast, United Kingdom; 2School of Pharmacy,
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Malfunction of innate defense mechanisms and the lack of mucocilliary clearance in
the airways promote primary and recurrent bacterial infections in cystic ﬁbrosis pa-
tients. Intensiﬁed usage of antibiotics in such patients has the adverse consequence
of increasing antimicrobial resistance and alternative therapeutic interventions are
urgently required. Antimicrobial cationic peptides are ubiquitous components of
the innate immune system acting as the ﬁrst line of defense against infectious
agents and are interesting candidates for use in CF therapy. In the current study,
a two-stage ultra sensitive radial diffusion assay was employed to determine the
antimicrobial activity of both human neutrophil peptide-1 (HNP-1) and a truncated
analogue (modelled on the C-terminal region; 2Abz23S29) against a panel of
respiratory pathogens. A clinical isolate of MRSA, a major nosocomial pathogen
with a progressive increased prevalence in CF populations was susceptible to both
HNP-1 and its truncated analogue. Interestingly MRSA was more susceptible to
both peptides (HNP-1 MIC value = 7.4mg/ml; 2Abz23S29 MIC value = 36.5mg/ml)
than a clinical isolate of MSSA (HNP-1 MIC value = 18.4mg/ml; 2Abz23S29 MIC
value = 50.1mg/ml). Clinical strains of P. aeruginosa displayed variable sensitivities
to HNP-1 and its truncated analogue in line with their reported sensitivities to
antibiotics. Members of the B. cepacia complex were resistant to both peptides. In
conclusion, the ﬁnding that HNP-1 and a truncated analogue (which lacks disulphide
bridges) display antimicrobial activity against MRSA, MSSA and P. aeruginosa
could aid their potential use in therapeutic interventions in CF patients.
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Background: Tobramycin (TOBI®) is widely used as a nebulised antibiotic in
subjects with CF. Previous safety and toxicity data has mainly been performed
using the Pari LC® Plus conventional nebuliser, yet many centres are increasingly
using advanced membrane or mesh based nebulisers, such as the eFlow®.
Aims: To measure peak serum tobramycin levels in children aged 2−16 years using
TOBI® via the eFlow®. To assess for renal and ototoxicity by measuring urinary
NAG (N-acetyl-beta-D-glucosaminidase) and assessing annual audiology reports
respectively.
Methods: 10 children attending Leeds CF Centre receiving 300mg TOBI® via
eFlow® for clinical reasons agreed to participate. Serum tobramycin levels were
obtained one hour post nebulisation. Eight provided samples for urinary NAG, and
nine underwent audiology.
Results: Mean age was 10.5 years (range 2 to 16). Serum tobramycin level was
below 1mg/L in 7 children, but the level was >1mg/L in 3 children (maximum
was 3.8). Two of the children with raised levels were 2 years old, the third was 11.
Urine NAG/Creatinine levels were raised (>0.47 umol/min/mmol) in 4 children,
1 of these had an elevated tobramycin level. Audiology results showed no change
except in 1 patient who had high frequency hearing loss.
Discussion: Serum tobramycin levels over 1mg/L can occur one hour post 300mg
TOBI® delivered by eFlow®. Raised urinary NAG levels suggest that some children
may have some associated early renal toxicity. Further study is suggested to
determine whether TOBI® dosage should be adjusted for age or weight of the
paediatric patient when using eFlow®.
